Product Description
Monobenzone is the monobenzyl ether of hydroquinone. It is used as a topical drug for medical depigmentation. It has a role as a melanin synthesis inhibitor, a dermatologic drug and an allergen. It derives from a hydroquinone. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Monobenzone)
Mechanisms of Action: tyrosinase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | India | Poland | Portugal | Taiwan | Turkey | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|